Incyte's Ruxolitinib Shows Better Outcomes Regardless Of Organs Affected In GvHD Patients

·1 min read
  • Incyte Corporation (NASDAQ: INCY) has announced that positive data from the Phase 3 REACH3 study have been published in The New England Journal of Medicine (NEJM). The study is jointly sponsored by Incyte and Novartis AG (NYSE: NVS).

  • The publication includes data showing Jakafi (ruxolitinib) significantly improved overall response rate at Week 24 (49.7% vs. 25.6%) with a higher best overall response rate (76.4% vs. 60.4%) vs. best available therapy (BAT) in patients with steroid-refractory/dependent chronic graft-versus-host disease (GvHD).

  • In addition, a new subgroup analysis included in the publication found that patients on ruxolitinib had better outcomes regardless of the individual organs affected at baseline.

  • No new safety signals were observed in REACH3, and adverse events attributable to treatment were consistent with the known safety profile of ruxolitinib.

  • Mortality rates were similar across treatment arms (18.8% in the ruxolitinib arm vs. 16.5% in the BAT arm).

  • Deaths reported primarily due to chronic GVHD complications or treatment were higher in the ruxolitinib vs. BAT arms (13.3% vs. 7.9%, respectively).

  • The U.S. application is currently under review, with a target action date of September 22, 2021.

  • Price Action: INCY shares closed at $79.87 on Wednesday.

See more from Benzinga

© 2021 Benzinga does not provide investment advice. All rights reserved.